Oncotelic Therapeutics Inc.

Company

Related News

Oncotelic highlighted in editorial on biotech valuation and advancing drug pipelines

Apr 25, 2026

Oncotelic Therapeutics said it was featured in an editorial on how advancing drug pipelines are driving biotech valuation. The company cited its oncology pipeline, AI-enabled platform and 45% stake in GMP Bio.

Late-Stage CNS and Oncology Assets Drive Biotech M&A Strategy Shift

Feb 17, 2026

Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation over early-stage programs. Oncology and CNS programs have emerged as strategic M&A targets due to large commercial markets and significant unmet medical needs.